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ABSTRACT
Introduction: Rheumatoid arthritis (RA) is one
of the most common chronic inflammatory
diseases. The goal of this study was to analyze
the risk of depression in patients diagnosed
with RA and treated by general practitioners in
the UK.
Methods: The present study included patients
first diagnosed with RA between 2000 and 2014
(index date). Individuals were excluded if they
had also been diagnosed with depression or if
they had received therapy for depression at or
prior to the index date. The primary outcome
measure was the rate of patients with depression
(ICD 10: F32, 33) within 5 years of the RA
diagnosis. Demographic data included gender
and age. Furthermore, a revised version of the
Charlson comorbidity index was used as a gen-
eric marker of comorbidity.
Results: A total of 4187 patients were included
in the study. After 5 years of follow-up, 23.7% of
men and 36.5% of women had developed
depression (log rank p value \0.001). Women
were more likely to develop depression than
men (HR 1.61, 95% CI 1.42–1.84). Age and
Charlson comorbidity score had no significant
impact on the risk of being diagnosed with this
psychiatric disorder.
Conclusion: Around 30% of RA patients devel-
oped depression within 5 years of the RA diag-
nosis. The depression risk was higher in women
than in men. The current findings also indicate
that improved detection and treatment of
patients with both RA and depression are
important.
Keywords: Depression; Rheumatoid arthritis;
Risk factors; United Kingdom
INTRODUCTION
Rheumatoid arthritis (RA) is one of the most
common chronic inflammatory diseases [1, 2].
RA can affect joints, connective tissues, mus-
cles, tendons, and fibrous tissues [3]. This dis-
order has a prevalence of 0.3–1% and is known
to be more common in women and in devel-
oped countries [2]. In the United Kingdom
(UK), at least 1.16% of women and 0.44% of
men were found to be affected by RA [4].
Rheumatoid arthritis is considered a chronic
condition and has a major impact on the quality
of life of patients [5], thus underlying the
Enhanced content To view enhanced content for this
article go to http://www.medengine.com/Redeem/
C3F7F0602F129F4E.
L. Jacob
Faculty of Medicine, University of Paris 5, Paris,
France
T. Rockel  K. Kostev (&)




importance of personalized management and
treatment of people affected by this disease. In
2013, Matcham and colleagues discovered in a
systematic review and meta-analysis that the
prevalence of major depressive disorder was
around 17% in patients diagnosed with RA [6].
They further estimated that this prevalence was
significantly associated with age, with younger
patients being at a higher risk of developing
depression than older patients. Some have repor-
ted that gender is a risk factor for thedevelopment
ofdepression in individualsdiagnosedwithRA. In
2005, Ramjeet et al. estimated that women with
recent-onset inflammatory polyarthritis exhib-
ited higher levels of anxiety and depression than
men [7]. However, Mostafa and Radwan later
found no significant relationship between gender
and depression in RA patients [8]. Finally, a Tai-
wanese study showed that women with RA had a
greater risk of depression than men with RA [9].
Since these findings are controversial, we
decided to analyze the risk of depression in
patients diagnosed with RA and treated by
general practitioners (GPs) in the UK.
METHODS
Database
The Disease Analyzer database (IMS HEALTH)
compiles drug prescriptions, diagnoses, and
basic medical and demographic data obtained
directly and in anonymous format from com-
puter systems used in GP practices [10].
This database recorded multiple patient
characteristics (e.g., age, gender) and comor-
bidities (e.g., myocardial infarction, stroke,
cancer, diabetes) with sufficient data to allow
the calculation of the Charlson index, which
examines 22 comorbidities and demographic
factors (see below).
Diagnoses (ICD-10), prescriptions (Anatomi-
cal Therapeutic Chemical (ATC) Classification
System), and the quality of reported data are
monitored by IMS based on a range of criteria
(e.g., completeness of documentation, linkage
between diagnoses, and prescriptions).
In the UK, the sampling methods used to
select physicians’ practices were appropriate to
obtain a representative database of people with
RA [10]. The sampling method for the Disease
Analyzer database is based on statistics from all
doctors in the UK. These statistics are used to
determine the panel composition according to
the following strata: region, community size
category, and age of physician.
Study Population
Patients who were first diagnosed with RA
(ICD-10: M05, M06) between 2000 and 2014
were included in the present study. The date of
first RA diagnosis documentation by a GP was
considered the index date. Individuals were
excluded if they had also been diagnosed with
depression based on the ICD-10 criteria (F32,
F33) or if they had received therapy for depres-
sion (ATC: N06A) at or prior to the index date.
Formal ethical approval was not required for
this study according to German law (§15 BOA¨,
Medical Association’s professional code of con-
duct), as the study was based on anonymized
data. It was not possible to identify individual
patients. Therefore, informed consent was not
required (nor could it be received).
Study Outcome Measures
and Independent Variables
The primary outcome measure was the propor-
tion of patients diagnosed with depression
within 5 years of the diagnosis of RA. Patients
were followed up from January 2010 until June
2016. Demographic data included gender and
age. Furthermore, a revised version of the
Charlson comorbidity index (CCI) was used as a
generic marker of comorbidity [11]. The Charl-
son comorbidity index describes 22 comorbid
conditions where each condition is assigned a
score from 1 to 6 depending on the risk of dying
from it. Clinical conditions and associated
scores in the CCI are as follows: myocardial
infarction, congestive heart failure, peripheral
vascular disease, dementia, cerebrovascular dis-
ease, chronic lung disease, connective tissue
disease, ulcer, chronic liver disease, diabetes,
hemiplegia, moderate or severe kidney disease,
diabetes with end-organ damage, tumor,
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leukemia, lymphoma, moderate or severe liver
disease, malignant tumor, metastasis, and AIDS
[11]. CCI was included in order to estimate if a
higher RA patient comorbidity status is associ-
ated with a higher risk of depression.
Statistical Analysis
Descriptive analyses were obtained for all
demographic and clinical variables, and the
mean ± SD was calculated for normally dis-
tributed variables. Kaplan–Meier curves were
used to analyze the proportion of RA patients
diagnosed with depression. The Kaplan–Meier
curve is defined as the probability that an event
(for example, diagnosis) will occur within a
given length of time when time is discretized
into many small intervals. It provides a visual
representation of this probability in two or
more groups. The strength of Kaplan–Meier
analysis is that it includes patients who could
not be followed for the complete study duration
(for example, 5 years); these patients are
assumed to have the same event probability as
those who continue to be followed [12, 13].
Finally, a multivariate Cox regression model
was created to determine the impact of demo-
graphic and clinical variables on the risk of
being diagnosed with depression. In a Cox
regression model, the parameter of interest is
the time until the occurrence of an event (for
example, disease). Like Kaplan–Meier analyses,
Cox regression analyses also include patients
who could not be observed throughout the
entire study duration. The Cox regression uses a
proportional hazards model to calculate the
hazard ratio (HR), which shows the ratio of
event probabilities in the two groups [14].
p values \0.005 were considered statistically
significant. Analyses were carried out using SAS
version 9.3.
RESULTS
A total of 4187 patients were included in this
study. The mean age was 59.1 years (SD
17.8 years), and 34.3% were men. The mean
Charlson comorbidity score was 1.4 (SD 1.1).
Figure 1 displays Kaplan–Meier curves for the
time to depression diagnosis by gender, with
23.7% of men and 36.5% of women developing
depression within the 5-year follow-up period
(log rank p value\0.001).
Table 1 displays the results of themultivariate
Cox regression model. Women were more likely
to develop depression than men (HR 1.61, 95%
CI 1.42–1.84). Age and Charlson comorbidity
score had no significant impact on the risk of
being diagnosed with this psychiatric disorder.
DISCUSSION
In the present retrospective study, around 30%
of patients developed depression within 5 years
of RA diagnosis. We also found a 1.6-fold
increase in the risk of developing depression in
women compared to men.
RA is a chronic condition that has a sub-
stantial impact on health. In 2007, Haroon and
colleagues investigated 136 RA patients and 75
age-matched controls and discovered that
quality of life was compromised in individuals
diagnosed with RA [15]. The authors further
found a significant inverse correlation between
the activity of the disease and the physical and
psychological domains of quality of life. More
recently, a 2013 study performed in Brazil esti-
mated that moderate to severe RA was associ-
ated with major functional disability and
morbidity, with work and activity impairment
increasing with disease severity [16].
The impact of RA on depression has been the
focus of several works in the past decade. In
2002, Dickens et al. discovered in a systematic
review and meta-analysis of the literature that
depression was more frequent in individuals
with RA than in healthy individuals [17]. This
may be partially explained by the levels of pain
experienced by RA patients, thus clearly
underlying the importance of personalized
treatments and management for these patients.
In 2013, another meta-analysis of 72 studies
that included 13,189 patients found that the
prevalence of major depression was 16.8% (95%
CI 10–24%) [6]. According to the PHQ-9 test
questionnaire, depression prevalence was even
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higher and reached 38.8% (95% CI 34–43%).
Finally, the authors showed a significant rela-
tionship between mean age and the rate of
depression, with lower age being associated
with increased rates. In line with these findings,
the present study discovered that approxi-
mately 30% of patients were depressed within
5 years after the diagnosis of RA.
Such results are of particular concern because
depression is known to increase the risk of
mortality in RA patients [18]. The identification
of predictors of depression in this population is
very important and has been the focus of several
recent works [19–21]. In 2006, Covic and col-
leagues estimated that 12 variables correctly
classified around 80% of RA individuals into
depressed and nondepressed groups [19]. The
strongest predictors of this psychiatric
condition were high tension, low self-esteem,
and the perceived impact of RA. Interestingly,
fatigue, passive coping, pain, and physical dis-
ability had additional effects on the risk of
developing depression. Later, an American
study of 172 patients found that disease severity
(calculated using the Health Assessment Ques-
tionnaire, HAQ) and ethnicity were signifi-
cantly associated with depression [20]. Finally,
Lin and colleagues discovered in 2015 that
women, younger patients, and people with
comorbidities such as stroke, chronic kidney
disease, or cancer were at a particular risk of
depression [22]. The present retrospective study,
which included more than 4000 patients, also
showed that women were more likely to be
diagnosed with depression within the 5 years
following RA diagnosis compared to men.
Recently, the relationship between gender and
depression in RA has been the focus of several
studies. A 2005 UK analysis including 112
individuals affected by recent-onset inflamma-
tory polyarthritis showed that 36% of the pop-
ulation was at risk of depressive symptoms [7].
Furthermore, it was also found that women
displayed higher levels of depression than men,
although gender had no impact on levels of
disability or pain. Later, Mostafa and Radwan
discovered that the prevalence of depression in
an Egyptian population with RA was 15.29% [8].
The authors notably found positive correlations
between depression and age, disease duration,
and disease activity. In contrast, there was no
significant association with gender. More
recently, it was estimated in a Taiwanese anal-
ysis that included 3698 adults newly diagnosed
with RA that women, the elderly, and patients
with comorbidities were at a higher risk of
developing depression than men, younger
individuals, and patients free of comorbidities
[7, 9]. The association between gender and
depression or anxiety in RA might be explained
by the fact that men tend to adjust better to
their disease than women. Another possibility is
that male RA patients are less likely to reveal
their depressive symptoms to their doctor than
female RA patients. Finally, in the present
study, age and comorbidity had no significant
impact on depression. This difference may be
explained by the fact that the multivariate
Fig. 1 Kaplan–Meier curves for time to depression diag-
nosis in newly diagnosed RA patients by gender
Table 1 Association of depression with predeﬁned vari-





Women vs men 1.61 (1.42–1.84) \0.001
Age B40 vs[70 years 0.88 (0.74–1.05) 0.165
Age 41–50 vs[70 years 1.10 (0.92–1.32) 0.298
Age 51–60 vs[70 years 1.14 (0.96–1.34) 0.129
Age 61–70 vs[70 years 0.91 (0.77–1.09) 0.299
Charlson comorbidity index 1.04 (0.97–1.15) 0.159
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regression model was adjusted for inflamma-
tion, which is known to play a key role in both
depression and RA.
In general, retrospective primary care data-
base analyses are limited by the validity and
completeness of the data on which they are
based. The present study is subject to the fol-
lowing limitations. The assessment of diag-
noses was based solely on ICD codes entered
by general practitioners, and no information
was available regarding the procedure by
which depression diagnoses were made. Infor-
mation about whether depression diagnoses
were made by GPs themselves or by psychia-
trists was unavailable. Data on potential con-
founding variables such as socioeconomic
status, marital status, educational level, social
support, psychosocial stressors, and
lifestyle-related risk factors (body mass index,
smoking status, etc.) were also unavailable.
Unfortunately, no data on the severity of
inflammation were available. The strength of
the study is the large number of patients
available for analysis. Another strength is the
use of real-world data in primary care practices
where diagnoses are continuously docu-
mented, allowing for unbiased exposure
assessment (no recall bias).
CONCLUSIONS
Around 30% of RA patients developed depres-
sion within 5 years of the diagnosis of RA.
Women had a higher risk of being diagnosed
with depression in the 5 years following the
index date compared to men.
The current findings also indicate that
improved detection and treatment of patients
with RA and depression is needed.
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